期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

GDF15在铁过载及红系生成中的作用 被引量：3

Effect of GDF15 on Iron Overloading and Erythropoiesis—Review
下载PDF
导出
摘要 无效红细胞生成被认为是非输注性铁过载患者铁过载的主要原因,在扩增的红系生成过程中原始红细胞的凋亡诱导转化生长因子15(GDF15)上调,后者抑制肝细胞铁调素的分泌,从而增加肠道铁吸收,引发铁过载。生理剂量的GDF15能促进原始红细胞的分化成熟,而高剂量的GDF15抑制铁调素的分泌。机体内铁水平、表观遗传修饰及组织缺氧均可能与GDF15的调控相关,本文就GDF15的表达与分布,GDF15在红系生成和铁过载中的作用以及GDF15的调控因素等问题进行综述。 Ineffective erythropoiesis is recognized as the principal reason of non-transfusional iron overload.In the process of expanded erythropoiesis,the apoptosis of erythroblasts induces the up-regulation of GDF15.GDF15 suppresses hepcidin production by the hepatocytes.Subsequently,low hepcidin levels increase iron absorption from the intestine resulting in iron overload.Physiological dose of GDF15 can promote the growth and differentiation of erythroid progenitors,but the high dose of GDF15 can suppress the secretion of hepcidin.The regulation of GDF15 may also be related to iron levels,epigenetic regulation and hypoxia.In this article the GDF15 and its expression and distribution,roles of GDF15 in exythropoiesis and iron overload,as well as the regulation factors of GDF15 are reviewed.
作者 赵佑山 常春康
机构地区 上海交通大学附属第六人民医院血液科
出处 《中国实验血液学杂志》 CAS CSCD 2011年第2期537-541,共5页 Journal of Experimental Hematology
关键词 凋亡诱导转化生长因子15 红细胞生成 铁过载 GDF15 erythropoiesi iron overload
分类号 R331.141 [医药卫生—人体生理学]
  • 相关文献

参考文献30

  • 1聂玲,李磷,杨艺红,张战强,于明华,徐泽锋,郝玉书,肖志坚.骨髓增生异常综合征患者铁代谢状况及其对预后的影响[J].中华血液学杂志,2009,30(1):50-53. 被引量：3
  • 2Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica,2007 ; 92 (5) : 583 -588.
  • 3Tanno T, MiUer JL. Iron loading and overloading due to ineffective erythropoiesis. Adv Hematol, 2010; Published online, 2010; 1010:358283.
  • 4Mimeault M, Batra SK. Divergent molecular mechanisms under- lying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol,2010;224(3) :626 -635.
  • 5Dctmer K, Steele TA, Shoop MA, et al. Lineage-restricted expression of bone morphogenetic protein genes in human hematopoietie ceil lines. Blood Cells Mol Dis, 1999 ; 25 ( 5 - 6 ) : 310 - 323.
  • 6Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF-15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med,2007 ;13(9) :1096 -1101.
  • 7Ramirez JM, Schaad O, Durual S, et al. Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. Br J Haematol, 2009; 144 ( 2 ) :251 - 262.
  • 8Forejtnikovd H, Vieillevoye M, Zermati Y, et al. Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood, 2010; Sep 8 [ Epub ahead of print ].
  • 9Kemna EH, Tjalsma H, Willems IlL, et al. Hepcidin: from discovery to differential diagnosis. Haematologica,2008;93(1) :90 -97.
  • 10Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu Rev Patho,2009 ;4:489 -515.

二级参考文献7

  • 1Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide storey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol, 2007,78:487494.
  • 2Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum felTitin in patients undergoing myeloablative stem cell transplantation. Blood ,2007,109 : 4586-4588.
  • 3Leitch A, Goodman A, Wong K, et al. Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy. Blood (ASH Annual Meeting Abstracts), 2006,108: Abstract 249.
  • 4Varkonyi J, Tarkovacs G, Karddi I, et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haeumtol, 2003, 109:64- 67.
  • 5Nearman Z, Szpurka H, Serio B,et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol, 2007, 82 : 1076-1079.
  • 6Konen E, Ghoti H, Goitein O, et al. No evidence for myocardial iron overload in muhitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol,2007, 82 : 1013-1016.
  • 7Stone R. Elevated serum ferritin in patients with a myelodysplastic syndrome: how much of a problem? Am J Hematol,2008 ,83 :609- 610.

共引文献2

同被引文献50

  • 1Cazzola M. Risk assessmeni in myelodysplastic syndromes andmyelodysplastic/ myeloproliferative neoplasms. Haematologica,2011 ; 96(3) :349 -352.
  • 2Kaplan J,Ward DM,De Domenico I. The molecular basis of ironoverload disorders and iron-linked anemias. Int J Hematol. 2011 ;93(I):l4-20.
  • 3Tanno T,Porayette P,Sripichai O,et al. Identification of TWSG1as a second novel erythroid regulator of hepcidin expression inmurine and human cells of the iron regulatory protein hepcidin.Blood,2009; 114( 1 ) :181 -186.
  • 4Winder A,Lefkowitz R,Ghoti H,et a!. Urinary hepcidinexcretion in patients with myelodysplastic syndrome andmyelofibrosis. Br J Haematol,2008; 142(4) :669 -671.
  • 5Gattermann N. Clinical consequences of iron overload inmyelodysplastic syndromes and treatment with chelators. HematolOncol Clin North Am,2005 ; 19( Suppl 1):13 - 17.
  • 6Cabantchik ZI,Breuer W,Zanninelli G,et al. LPI-labile plasmairon in iron overload. Best Praci Res Clin Haematol ,2005; 18(2):277 -287.
  • 7Kell DB. Iron behaving badly:inappropriate iron chelation as amajor conlributor to the aetiology of vascular and other progressiveinflammatory and degenerative diseases. BMC Med Genet,2009 ;2:2.
  • 8Prus E,Fibach E. Flow cytometry measurement of the labile ironpool in human hematopoietic cells. Cytometry A,2008 ; 73( 1) :22-27.
  • 9Petrat F,de Groot H,Sustmann R,et al. The chelatable iron poolin living cells:A methodically defined quantity. Biol Chem,2002;383(3 -4):489-502.
  • 10Cohen AR,Porter JB. Transfusion and iron chelation therapy inthalussemia cord sickle cell anemia,In:MHea S. Disorders ofHemoglobin :Genetics,Pathophysiology,and Clinical Manage-ment. Cambridge,Cambridge University Press,2001:979 -1027.

引证文献3

二级引证文献10

中国实验血液学杂志
2011年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部